Kira Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE,Mass. and SUZHOU,China,Jan. 12,2021 --Kira Pharmaceuticals,a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases,today announced that Frederick Beddingfield,Chief Executive Officer of Kira Pharmaceuticals,will present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday,Jan. 13,2021 at 11:35 AM ET.

The presentation will be accessible via a live webcast at:

https://jpmorgan.metameetings.net/events/healthcare21/sessions/35931-kira-pharmaceuticals/webcast?gpu_only=true&kiosk=true

Audio of the presentation will also be posted to the Kira Pharmaceuticals website (www.kirapharma.com) for up to 30 days following the meeting.

Last week,Kira announced the company completed a $53.5 million Series B+ financing to advance its LOGIC discovery platform and a pipeline of complement-targeted therapies. Kira also announced plans to file three investigational new drug applications over the next 18 months. The company's most advanced program,P014,is a first-in-class biologic molecule with a unique mechanism of action designed to inhibit both upstream and downstream complement targets.

About Kira Pharmaceuticals

Kira Pharmaceuticals is a biotechnology company developing complement-targeted therapies to treat immune-mediated diseases. Enabled by its LOGIC drug discovery platform,the company is committed to advancing first-in-class and best-in-class therapies to transform the lives of patients with complement-driven diseases. With offices in Cambridge,Massachusetts and an R&D center in Suzhou,Kira Pharmaceuticals is committed to establishing a global footprint and advancing life-changing therapies to patients around the world.

For more information,please visit www.kirapharma.com.

Logo - http://cusmail.com/res/2023/07-22/19/b289ee2756f9dc0a86e09a2f2f139c72.jpg